Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Nektar Therapeutics : Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News

share with twitter share with LinkedIn share with facebook
share via e-mail
03/21/2017 | 02:31pm CET
NEW YORK, NY / ACCESSWIRE / March 21, 2017 / For biotech firms, there generally is not much news that will thrills investors. Generally, investors do not expect much from their investment for years as the drug or technology goes through the FDA approval process, which can take 3 years or longer. For these two firms, today was a day for investors to start to celebrate, as one received an important extension from a major pharmaceutical firm, while another makes a breakthrough by breaking from convention.

RDI Initiates Coverage:

Nektar Therapeutics https://ub.rdinvesting.com/news/?ticker=NKTR

CytomX Therapeutics Inc. https://ub.rdinvesting.com/news/?ticker=CTMX

The company announced significant positive news from its current drug candidate, NKTR-181. The Phase 3 efficacy study of the drug NKTR-181, which is a first in its class of opioid analgesics indicated the new chemical entity (NCE) that is the first full mu-opioid drug was effective to provide potent pain relief to patients without the high levels of euphoria that a major contributor to drug abuse and addiction that accompany standard opioids. The company's stock rose $6.61 a share with significantly higher volume to close at $22.21, a decade high. After hours trading showed the stock price continuing to rise. With the granted fast-track designation of NKTR-181, investors are feeling bullish on prospect of improving bottom line, as the company management has indicated in the last conference call about their plan to out-license the drug to an established player and a company with long-term commitment in the pain market. In the ongoing battle against opioid abuse and addiction, the discovery and creation of an opioid pain killer that is safe and non-addictive is a major step in the war against the illegal distribution and sale of prescription drugs.

Access RDI's Nektar Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=NKTR

One way a small cap biotech firm can get a boost in stock price is by having the confidence of an established pharmaceutical company get behind it. That is exactly what happened to CytomX Therapeutics on Monday, as Bristol-Myers Squibb Company and CytomX announced their expansion of the 2014 strategic collaboration agreement. CytomX is in the process of discovering new therapies for cancer treatment. There are 8 other candidates that will be using CytomX's proprietary Probody platform. The stock rose $3.71 a share to close at $18.89 per share on Monday. It closed at $15.20 a share on Friday. Earlier this month on March 2nd, the company posted it 2016 full year financials, with a loss of $1.63 a share on a revenue of $15 million for the year 2016, as compared to loss of $4.9 a share on revenue of $7.7 million reported for the year 2015. The company had cash and cash equivalents along with short-term investments of $181.9 million and this the company expects is sufficient enough to sail throughout 2018 to fund its operations without any additional capital infusion.

Access RDI's CytomX Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CTMX

Our Actionable Research on Nektar Therapeutics (NASDAQ: NKTR) and CytomX Therapeutics Inc. (NASDAQ: CTMX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011



CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
03/21 NEKTAR THERAPEUTICS : Stocks of Nektar Therapeutics and CytomX Therapeutics Rise..
03/20 Dominion Diamond and Nektar climb; Wells Fargo dips
03/20 NEKTAR THERAPEUTICS : Biotech Stocks Showing Strong Move To The Upside
03/20 NEKTAR THERAPEUTICS (NASDAQ : NKTR) Files An 8-K Regulation FD Disclosure
03/20 NEKTAR THERAPEUTICS : NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 ..
03/20 NEKTAR THERAPEUTICS : Regulation FD Disclosure, Financial Statements and Exhibit..
03/03 NEKTAR THERAPEUTICS : to Webcast Presentation at Cowen and Company's 37th Annual..
03/02 NEKTAR THERAPEUTICS : Clinical Data from Phase 1 Dose-Escalation Study of Single..
03/01 NEKTAR THERAPEUTICS : reports 4Q loss
03/01 NEKTAR THERAPEUTICS (NASDAQ : NKTR) Files An 8-K Results of Operations and Finan..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/21 Nektar Reaches The Summit
03/21 Nektar Therapeutics (NKTR) SUMMIT-07 Phase 3 Study Presentation - Slideshow
03/20 Midday Gainers / Losers
Financials ($)
Sales 2017 165 M
EBIT 2017 -161 M
Net income 2017 -204 M
Debt 2017 224 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 22,8x
EV / Sales 2018 16,8x
Capitalization 3 521 M
More Financials
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 8
Average target price 25,0 $
Spread / Average Target 9,2%
Consensus details
EPS Revisions
More Estimates Revisions
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG4.76%10 574
CELLTRION, INC.--.--%9 774
ALKERMES PLC6.93%9 066
More Results